Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gadoteridol
Drug ID BADD_D00993
Description Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.
Indications and Usage Gadoteridol is an MRI contrast agent used for contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.
Marketing Status approved; investigational
ATC Code V08CA04
DrugBank ID DB00597
KEGG ID D01137
MeSH ID C062402
PubChem ID 60714
TTD Drug ID D0M1PL
NDC Product Code 0270-1111; 57876-111; 73435-009
UNII 0199MV609F
Synonyms gadoteridol | Gd-HP-DO3A | gadolinium 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane | GdHPDO3A | Gd-hydroxypropyl-D03A | gadolinium 1,4,7-tris(carboxymethyl)-10-(2'-hydroxypropyl)-1,4,7,10-tetraazacyclododecane | gadolinium HP-DO3A | Gd-HPDO3A | Gd(DO3A) | Gd-HP-D03A | Prohance | SQ 32692 | SQ 32,692 | SQ-32692
Chemical Information
Molecular Formula C17H29GdN4O7
CAS Registry Number 120066-54-8
SMILES CC(CN1CCN(CCN(CCN(CC1)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])O.[Gd+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Deafness transitory17.04.07.003; 04.02.01.004--Not Available
Death08.04.01.001--
Defaecation urgency07.02.04.0010.015649%Not Available
Depressed level of consciousness17.02.04.002--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disturbance in attention19.21.02.002; 17.03.03.0010.007113%
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.108123%
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.0010.019206%
Dysphagia07.01.06.0030.029876%
Dysphonia17.02.08.004; 22.12.03.006; 19.19.03.0020.017783%
Dyspnoea02.11.05.003; 22.02.01.0040.172855%
Epilepsy17.12.03.0020.010670%Not Available
Erythema23.03.06.0010.047660%Not Available
Eye irritation06.04.05.0030.024186%Not Available
Eye swelling06.08.03.0030.010670%Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Feeling abnormal08.01.09.014--Not Available
Feeling cold08.01.09.0080.031299%Not Available
Feeling hot08.01.09.0090.062598%Not Available
Fluid retention14.05.06.002; 20.01.02.003--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.0250.034856%
Gait disturbance17.02.05.016; 08.01.02.002; 15.03.05.0130.010670%
Generalised oedema14.05.06.007; 08.01.07.004--
Gingivitis07.09.10.002; 11.01.04.013--
Glossodynia07.14.02.001--Not Available
Headache17.14.01.001--
Heart rate increased13.14.04.002--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages